Ann: PhII smoking cessation - dosing complete analysis underway, page-11

I would hope there would be an announcement soon. IMO the shareprice is languishing at record lows because of a lack of information. At the AGM late last year, our CEO outlined milestones for the next 12 - 18 months. One of them was completion and final data from Invion 103 phase 2 study in lupus. He has been talking about a partnering opportunity now for over 12 months. We can only presume that potential partners must be waiting for this final data.
However,there is no indication or announcement from the company that this trial has completed enrolment or dosing. The clinical trial website says the trial is still recruiting ( I presume for 300mg dosage?).
Shareholders must be very excited with the Nadolol Invion 102 trial to date and we are being expertly updated, however there are long term holders like myself who believe in the science behind CPN10.... but we are getting nothing but missed deadlines and silence.